Antisoma shares rise on Phase II prostate cancer trial

LONDON (MarketWatch) -- Antisoma
uk:asm
shares rose 4.6% in London trade after the firm reported positive interim findings from a Phase II trial of AS1404 in a form of prostate cancer. Antisoma said final data are expected during the first half of this year, with time to tumor progression and survival data to follow in the second half.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.